Progyny (NASDAQ:PGNY) Reaches New 1-Year High After Analyst Upgrade

Progyny, Inc. (NASDAQ:PGNY – Get Free Report) shares reached a new 52-week high during trading on Wednesday after Zacks Research upgraded the stock from a hold rating to a strong-buy rating. The stock traded as high as $37.21 and last traded at $36.2850, with a volume of 35,270 shares traded. The stock had previously closed at $36.71.

Several other research analysts also recently weighed in on PGNY. Citigroup restated a “market outperform” rating on shares of Progyny in a research note on Thursday, November 5th. Truist Financial reissued a “buy” rating and set a $42.00 target price (up from $36.00) on shares of Progyny in a research report on Tuesday. Jefferies Financial Group set a $33.00 price target on Progyny in a research report on Tuesday, September 8th. Canaccord Genuity Group set a $35.00 price target on Progyny in a research note on Friday, August 7th. Finally, Citizens Jmp increased their price objective on Progyny from $33.00 to $38.00 and gave the company a “market outperform” rating in a report on Thursday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $35.83.

View Our Latest Stock Analysis on Progyny

Insider Buying and Selling at Progyny

In other news, CFO Mark Livingston sold 2,139 shares of Progyny stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $30.00, for a total transaction of $64,170.00. Following the completion of the transaction, the chief financial officer directly owned 70,314 shares of the company’s stock, valued at $2,109,420. The trade was a 2.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Geoffrey Clapp sold 774 shares of Progyny stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $36.41, for a total transaction of $28,181.34. Following the completion of the transaction, the insider directly owned 58,235 shares of the company’s stock, valued at $2,120,336.35. The trade was a 1.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 630,072 shares of company stock worth $22,363,084. 9.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of PGNY. Public Employees Retirement System of Ohio acquired a new stake in Progyny in the 2nd quarter worth about $29,000. Nykredit A S acquired a new stake in Progyny during the second quarter worth about $38,000. IFP Advisors Inc raised its position in shares of Progyny by 376.0% during the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock valued at $57,000 after buying an additional 1,549 shares during the period. Toth Financial Advisory Corp purchased a new stake in shares of Progyny during the 2nd quarter valued at approximately $65,000. Finally, Kovack Advisors Inc. acquired a new position in Progyny in the third quarter valued at approximately $72,000. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Price Performance

The stock has a market capitalization of $2.61 billion, a price-to-earnings ratio of 32.52, a PEG ratio of 1.66 and a beta of 0.97. The business has a fifty day moving average of $29.24 and a 200 day moving average of $25.12.

Progyny (NASDAQ:PGNY – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.21. Progyny had a return on equity of 19.82% and a net margin of 6.80%. The company had revenue of $341.25 million during the quarter, compared to analysts’ expectations of $340.76 million. During the same quarter last year, the firm earned $0.15 earnings per share. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. On average, equities research analysts expect that Progyny, Inc. will post 1.43 EPS for the current year.

Progyny Company Profile

(Get Free Report)

Progyny, Inc. provides fertility and family-building benefits to employers and their employees. Its services are designed to help members navigate care options, access fertility specialists and receive support throughout treatment. The company’s offerings include coverage for treatments such as in vitro fertilization and egg freezing, along with fertility medications through its pharmacy benefit. Progyny also supports other family-building paths, including adoption and surrogacy, depending on the plan selected by an employer.

Featured Stories

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.